01—Abstract
Summary
Summary of the 8-K filed April 25, 2024. Cited figures are marked; the original filing is the authoritative source.
Merck reported first-quarter 2024 sales of $15.8 billiona, up 9% from the prior year (12% excluding foreign exchange).
Growth was led by oncology and vaccines: KEYTRUDA sales rose 20% to $6.9 billionb (24% excluding FX), and GARDASIL/GARDASIL 9 rose 14% to $2.2 billion (17% excluding FX). Diabetes was the main drag, with JANUVIA/JANUMET down 24%. GAAP EPS was $1.87 and non-GAAP EPS was $2.07, both including a $0.26 per-share charge for the Harpoon acquisition.
The GAAP gross margin improved to 77.6% from 72.9%, mainly from product mix, lower royalty rates on KEYTRUDA and GARDASIL, and lower amortization of intangibles. Management raised and narrowed its full-year 2024 outlook. Sales are now expected at $63.1 billion to $64.3 billionc (previously $62.7 billion to $64.2 billion), and non-GAAP EPS at $8.53 to $8.65 (previously $8.44 to $8.59).
The guidance includes roughly 3% negative FX impact on sales and about $0.30d per share of negative FX impact on EPS, largely attributable to the Argentine peso. The outlook does not assume additional significant business development deals. Merck also completed the Harpoon acquisition and agreed to acquire Elanco's aqua business, and WINREVAIR received FDA approval for pulmonary arterial hypertension.
For investors, the key points are the strength of the KEYTRUDA franchise, the upward revision to earnings guidance, and the pipeline catalysts ahead. Three FDA target action dates fall in the second quarter of 2024 (V116, KEYTRUDA in endometrial cancer, and patritumab deruxtecan), and an Oncology Investor Event is scheduled for June 3, 2024. Risks include continued declines in the diabetes franchise, generic competition in Europe and Asia Pacific, currency volatility, and the possibility of additional business development charges that the outlook excludes.
02—Key points
Key Highlights
- Q1 2024 sales of $15.8 billion grew 9% year over year (12% excluding FX), driven by oncology and vaccines.
- KEYTRUDA sales rose 20% to $6.9 billion (24% ex-FX), supported by earlier-stage indications and NSCLC uptake in the U.S.
- GAAP EPS was $1.87 and non-GAAP EPS was $2.07, both including a $0.26 per-share charge for the Harpoon acquisition, compared with $1.11 and $1.40 in Q1 2023.
- GAAP gross margin expanded to 77.6% from 72.9%, and non-GAAP gross margin to 81.2% from 76.9%, reflecting favorable product mix and lower royalty rates on KEYTRUDA and GARDASIL.
- Full-year 2024 sales guidance was raised and narrowed to $63.1 to $64.3 billion, and non-GAAP EPS guidance to $8.53 to $8.65 from $8.44 to $8.59.
- The FDA approved WINREVAIR, the first activin signaling inhibitor for pulmonary arterial hypertension, and Merck completed the Harpoon acquisition and agreed to acquire Elanco's aqua business.
- JANUVIA/JANUMET sales fell 24% to $670 million on U.S. pricing and demand pressure and European generic competition, and the diabetes franchise remains a headwind.
03—Questions
Frequently Asked Questions
Why did Merck raise its 2024 guidance?
Management cited continued strong global demand for key growth products in oncology and vaccines, particularly KEYTRUDA and GARDASIL/GARDASIL 9. The company raised its sales range to $63.1 to $64.3 billion and its non-GAAP EPS range to $8.53 to $8.65. The EPS guidance includes the $0.26 Harpoon charge and roughly $0.30 per share of negative FX impact.
How much of the EPS result was affected by one-time charges?
Both GAAP and non-GAAP EPS of $1.87 and $2.07, respectively, include a $0.26 per-share charge tied to the Harpoon acquisition, which included a $656 million R&D charge. Non-GAAP results exclude acquisition- and divestiture-related costs, restructuring costs, and investment gains or losses, which total $0.20 per share in the reconciliation.
What is the outlook for KEYTRUDA and the pipeline in the near term?
KEYTRUDA remains the core growth driver, and the FDA granted Priority Review to an sBLA for endometrial cancer. Three PDUFA dates fall in the second quarter of 2024: V116 (June 17), KEYTRUDA plus chemotherapy for endometrial carcinoma (June 21), and patritumab deruxtecan for EGFR-mutated NSCLC (June 26). An Oncology Investor Event is scheduled for June 3, 2024.
What are the main risks to Merck's results highlighted in the filing?
The filing points to continued decline in diabetes sales, generic competition for BRIDION and JANUVIA in Europe and Asia Pacific, FX volatility (especially the Argentine peso), and pricing and regulatory pressure in the U.S. and internationally. The outlook also excludes additional significant business development deals and future charges, which could materially affect GAAP results.
04—Continue